Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4744993 | 0.99 | DRD2 (0.44) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4744482 | 0.98 | MEN1 (0.46) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4747163 | 0.98 | MEN1 (0.45) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4748790 | 0.97 | DRD2 (0.46) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4744828 | 0.94 | DRD2 (0.43) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4748282 | 0.94 | DRD2 (0.45) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4747840 | 0.93 | MEN1 (0.44) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4748742 | 0.93 | KMT2A (0.52) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4747647 | 0.92 | MEN1 (0.46) | DRD2MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL4747097 | 0.92 | MEN1 (0.46) | DRD2MEN1KMT2AALDH1A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008117148-A1 | SUBSTITUTED OXADIAZOLE ANALOGS AS CALCIUM CHANNEL ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PREC MEDICINES INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2021-02-11 | — | — | US | disclosed |
| WO-2018118101-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2008117148-A1 | SUBSTITUTED OXADIAZOLE ANALOGS AS CALCIUM CHANNEL ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008117148-A1 | SUBSTITUTED OXADIAZOLE ANALOGS AS CALCIUM CHANNEL ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | APP, CACNA1G, CACNA1B | DRD2 3952/4885MEN1 1334/4885KMT2A 4104/4885 |
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CACNA1G, CACNA1H, CACNA1I | DRD2 2751/4885MEN1 1786/4885KMT2A 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.